COYA Coya Therapeutics, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1835022 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY17.6%
TTM net income YoY-63.7%
TTM EPS YoY-25.2%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-675.3%
Net margin-643.5%
FCF margin—
EBITDA margin-675.0%
Returns
ROE-99.2%
ROA-84.6%
ROIC (approx.)—
Asset turnover0.13x
Leverage & solvency
Liabilities / assets14.6%
Debt / equity0.00x
Current ratio7.24x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.72x
Accruals ratio-23.4%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $7.95M | $3.55M | $6.00M | $0 | — |
| R&D expense | $16.73M | $11.87M | $5.50M | $4.41M | $2.54M |
| SG&A expense | $11.45M | $8.89M | $7.83M | $4.85M | $2.31M |
| Operating income | -$22.56M | -$17.25M | -$7.90M | -$9.81M | -$4.87M |
| Pretax income | -$21.22M | -$15.60M | -$7.26M | -$12.24M | — |
| Income tax | $3,089 | -$720,287 | $723,852 | $0 | — |
| Net income | -$21.23M | -$14.88M | -$7.99M | -$12.24M | -$4.89M |
| EBITDA | -$22.53M | -$17.22M | -$7.88M | -$9.78M | -$4.85M |
| EPS (basic) | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 |
| EPS (diluted) | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 |
| Weighted avg. shares (diluted) | 16.73M | 15.24M | 10.16M | 2.59M | 2.59M |
| Balance sheet | |||||
| Cash & equivalents | $46.82M | $38.34M | $32.63M | $5.93M | $4.34M |
| Current assets | $49.94M | $44.31M | $41.20M | $7.18M | $4.58M |
| PP&E, net | $11,227 | $38,588 | $65,949 | $93,310 | $120,671 |
| Total assets | $49.95M | $44.35M | $41.26M | $8.40M | $4.79M |
| Current liabilities | $5.87M | $3.82M | $5.05M | $3.82M | $1.15M |
| Total liabilities | $6.92M | $4.77M | $5.63M | $16.79M | $1.15M |
| Shareholders' equity | $43.03M | $39.58M | $35.64M | -$8.39M | $3.64M |
| Shares outstanding | 20.93M | 16.71M | 14.41M | 2.59M | 2.59M |
| Cash flow statement | |||||
| Operating cash flow | -$10.74M | -$10.29M | -$11.19M | -$7.24M | -$3.90M |
| Investing cash flow | -$1.16M | -$25,000 | -$543,186 | -$525,000 | -$136,804 |
| Financing cash flow | $20.39M | $16.03M | $38.43M | $9.36M | -$340,584 |
| Depreciation & amortization | $27,361 | $27,361 | $27,361 | $27,361 | $16,133 |
| Stock-based compensation | $4.29M | $2.66M | $872,248 | $207,346 | $233,222 |
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.